Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based biopharmaceutical company Xoma has initiated new therapeutic antibody programs under an existing antibody discovery and development collaboration with Takeda.
Subscribe to our email newsletter
According to Xoma, the new programs add to the multiple discovery and development programs already being advanced through the collaboration.
Xoma said that, in collaboration with a number of world-class companies and institutions, it is engaged in more than 10 product development programs. These programs focus on multiple therapeutic areas including oncology, cardiovascular, anti-inflammatory and infectious diseases.
In November 2006 Xoma and Takeda initiated a collaboration in which Xoma is using its extensive collection of antibody phage display libraries and antibody optimization technologies to discover therapeutic antibodies in multiple therapeutic areas.
Steven Engle, chairman and CEO of Xoma, said: “Since 2006, Takeda and Xoma have worked together on antibody development. We are pleased with the evolution of our collaboration and the confidence Takeda has shown in our ability to help advance valuable pipeline candidates.”